Drug Approval | January 31, 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
The registered capital of the newly founded company is € 50 million
The new campus has been designed as an employee-centred experience and ecosystem zone
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
An accomplished R&D leader and champion of the application of AI to drug discovery
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Subscribe To Our Newsletter & Stay Updated
